2022
DOI: 10.3390/vaccines10060882
|View full text |Cite
|
Sign up to set email alerts
|

Vaccine Response in the Immunocompromised Patient with Focus on Cellular Immunity

Abstract: During the last few years, we have experienced a shift in how we evaluate the effectiveness of vaccines [...]

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 18 publications
0
1
0
Order By: Relevance
“…Only Addavax and Y2/ZnCar produced a significantly higher ( p ≤ 0.01) frequency of GC B-cells when compared to sucrose control; however, the frequency of GC B-cells produced by Y2/ZnCar was not statistically different from that by ZnCar-Y2 (Figure C). Overall, these data reveal that ZnCar-CpG produces a more robust cellular immune response when compared to Addavax, which is important in generating protection, especially in those who are immunocompromised. , …”
Section: Resultsmentioning
confidence: 77%
“…Only Addavax and Y2/ZnCar produced a significantly higher ( p ≤ 0.01) frequency of GC B-cells when compared to sucrose control; however, the frequency of GC B-cells produced by Y2/ZnCar was not statistically different from that by ZnCar-Y2 (Figure C). Overall, these data reveal that ZnCar-CpG produces a more robust cellular immune response when compared to Addavax, which is important in generating protection, especially in those who are immunocompromised. , …”
Section: Resultsmentioning
confidence: 77%